Can a shot help people with high IgE eat more foods safely?
NCT ID NCT06934200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether omalizumab injections, given every two weeks for 24 weeks, can help people aged 1 to 55 with high IgE levels tolerate more of their trigger foods. Participants who respond may then try adding the food to their diet with extra injections. The goal is to see if this approach is safe and effective for those who don't qualify for standard dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
omalizumab injections
What this could lead to
If successful, this could offer a new treatment option for people with food allergies who have high IgE levels, potentially allowing them to safely eat small amounts of trigger foods.
What could go wrong
This is a small, early-phase trial with only 32 participants. The treatment may not work for everyone, and there is a risk of allergic reactions during food challenges.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD HYPERSENSITIVITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••